---
slug: semaglutide-glp1-agonists
title: "semaglutide glp1 agonists"
kind: standard
status: published
hash: 4b97a2982dcbb6cd96f2dcc983306c7e074e2b01969550b0b48e6f86d0d0a299
created: 2026-06-29T17:47:38.507Z
updated: 2026-10-08T11:49:29.748Z
summary: "Evidence is being populated by Grok web"
tags: []
above: []
below: []
adjacent: []
nested: []
---
# semaglutide glp1 agonists

*Evidence is being populated by Grok web*

## Overview
Evidence is being populated by Grok web search.

## Facts

```json
{
  "converted_from": "markdown",
  "original_updated": "2026-06-29T17:47:40.716Z",
  "register": "standard",
  "category": null
}
```

## Sources

1. [Trends in glucagon-like peptide 1 receptor agonist prescribing patterns](https://pubmed.ncbi.nlm.nih.gov/40829097/) — “From 2018 to 2023, GLP-1 RA prescribing increased significantly, with semaglutide approved for weight loss rising to 60% share in the nondiabetic obese/overweight group.” (sha256 0fd029c6a70cfe03)
2. [GLP-1 receptor agonists for weight loss: A systematic review and meta-analysis of randomized controlled trials](https://pubmed.ncbi.nlm.nih.gov/41824845/) — “GLP-1 receptor agonists significantly increase the likelihood of weight loss versus placebo, with tirzepatide and semaglutide demonstrating the greatest relative efficacy among agents evaluated.” (sha256 e1ded765184f66c5)
3. [Semaglutide versus other GLP-1 receptor agonists in patients with MASLD](https://pubmed.ncbi.nlm.nih.gov/40536520/) — “Compared to other GLP-1RAs, semaglutide was associated with a 14% lower risk of primary composite outcomes... reduced risks of all-cause mortality (aHR, 0.68) and major adverse liver outcomes (aHR, 0.79).” (sha256 e13ccc054838bd33)
4. [Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy Range (OASIS 4)](https://clinicaltrials.gov/study/NCT05564117) — “Participants will either get semaglutide 25 milligram (mg) once daily or placebo once daily. This study will last for 72 weeks...” (sha256 df3ae37c0a325210)
5. [A systematic review and meta-analysis of the efficacy and safety of GLP-1 receptor agonists](https://www.nature.com/articles/s41591-025-03978-z) — “Semaglutide was effective in reducing major adverse cardiovascular events and reducing pain in knee osteoarthritis. Tirzepatide was effective in...” (sha256 da4300d821b85c11)